Retrospective 17 rheumatoid arthritis COVID-19+ patients, 7 on HCQ treatment, showing no significant differences. They study reports only including hospitalized patients, but the results include non-hospitalized patients. Results do not reflect any difference in the probability of a serious enough case to be tested and identified. Few group details are provided (even the age of patients in each group is not specified).
Küçükakkaş et al., 7/20/2021, retrospective, Turkey, Europe, preprint, 2 authors.
risk of ICU admission, 42.9% higher, RR 1.43, p = 1.00, treatment 1 of 7 (14.3%), control 1 of 10 (10.0%).
This study is excluded in the after exclusion results of meta analysis: minimal details of groups provided.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.